newsfilter
← Latest News
GlobeNewswire·

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New ZealandPhase 2